The Diagnostics Pipeline: FDA Proceeds without Congress Over LDTs Reform
The agency recently sent its own proposed LDTs regulation rule to the White House Office of Information and Regulatory Affairs for review.
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article